MedTrace Logo

A a Single Dose Efficacy Study in Inducing Laxation in Advance Illness Patients

NCT00401362 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 154

Last updated 2019-11-25

No results posted yet for this study

Summary

To test the effectiveness of MNTX in advanced illness subjects.

Conditions

  • Advanced Illness Patients With Opioid Induced Constipation

Interventions

DRUG

SC Methylnaltrexone

Dose 1

DRUG

SC Placebo

DRUG

SC Methylnaltrexone

Dose 2

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Bausch Health Americas, Inc.

    lead INDUSTRY

Principal Investigators

  • Tage Ramakrishna, MD · Progenics Pharmaceuticals, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-02-28
Primary Completion
2005-02-28
Completion
2005-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00401362 on ClinicalTrials.gov